Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 20 December 2021

Date: 20/12/2021
Location: Online

This extraordinary meeting is organised to discuss the evaluation of the conditional marketing authorisation application for Nuvaxovid (also known as NVX-CoV2373), a COVID-19 vaccine developed by Novavax.

EMA will communicate on the outcome of the meeting. 

The Committee for Medicinal Products for Human Use (CHMP) is responsible for preparing the European Medicines Agency's opinions on all questions concerning human medicines.

How useful was this page?

Add your rating
Average
58 ratings
3 ratings
1 rating
2 ratings